ANI Pharmaceuticals, Inc. ANIP
71.25 USD +3.46 (+5.10%)
At closeNov 10, 2026, 4:01 PM EST
71.25 0.00 0.00%
After hours · Nov 10, 4:01 PM ET
67.53 Day range 71.36
67.14 52-week range 90.73
- YTD
- -9.74%
- 1 year
- -19.88%
- Market cap
- 1.62B
- Revenue (ttm)
- 1.04B
- Profit margin
- 11.22%
- EPS (ttm)
- 5.03
- Shares out
- 22.72M
- P/E ratio
- 14.16
- Forward P/E
- 7.04
- YTD return
- -9.74%
- 1-year return
- -19.88%
- Volume
- 997.52K
- Avg volume
- 393.49K
- Open
- 67.53
- Previous close
- 67.79
- Day's range
- 67.53 – 71.36
- 52-week range
- 67.14 – 90.73
- Beta
- 0.47
- Analysts
- Buy
- Price target
- 105.22 (+47.7%)
- Earnings date
- Nov 5, 2026
5D -3.92 (-5.39%)
Key statistics
- Enterprise value
- 1.62B
- PEG ratio
- 1.68
- Price / sales
- 1.56
- Price / book
- 2.39
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 27.60%
- Free cash flow
- 184.05M
- Total cash
- 436.97M
- Total debt
- 617.36M
- Return on equity
- 20.45%
- Short % of float
- 18.48%
- 50-day average
- 72.42
- 200-day average
- 77.20
Analyst view
Consensus: buy
Buy
Price target (mean) 105.22 +47.7% upside
Now 71.25
- Target (low)
- 85.00
- Target (mean)
- 105.22
- Target (high)
- 121.00
Ratings (0m) 9 7 buy · 2 hold · 0 sell
- Strong buy3
- Buy4
- Hold2
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate 2.56.
Financials — quick view
ANIP Revenue — quarterly 290.78M
ANIP Net income — quarterly 35.15M
ANIP EPS — quarterly 1.54
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | 2.18 | — | — | — |
| Aug 7, 2026 | Jun 30, 2026 | 2.04 | 2.21 | +0.17 | +8.33% |
| May 8, 2026 | Mar 31, 2026 | 1.28 | 2.05 | +0.77 | +60.16% |
| Feb 27, 2026 | Dec 31, 2025 | 1.99 | 2.33 | +0.34 | +17.09% |
| Nov 7, 2025 | Sep 30, 2025 | 1.74 | 2.04 | +0.30 | +17.24% |
| Aug 8, 2025 | Jun 30, 2025 | 1.38 | 1.80 | +0.42 | +30.43% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2026 | Guggenheim | main | Buy | Buy |
| Sep 23, 2026 | Oppenheimer | init | — | Perform |
| Aug 10, 2026 | Guggenheim | main | Buy | Buy |
| Aug 10, 2026 | Canaccord Genuity | main | Hold | Hold |
| Jul 17, 2026 | Canaccord Genuity | init | — | Hold |
| Jul 10, 2026 | Guggenheim | reit | Buy | Buy |
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Princeton, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- anipharmaceuticals.com
News
ANI Pharmaceuticals, Inc. (ANIP) Q3 2026 Earnings Call Transcript 
Guggenheim Maintains Buy on ANI Pharmaceuticals, Raises Price Target to $121 
ANI Pharmaceuticals Q3 2026 Earnings Call Transcript 
ANI Pharmaceuticals (ANIP) Surpasses Q3 Earnings and Revenue Estimates 
ANI Pharmaceuticals Q3 Adj. EPS $2.70 Beats $2.18 Estimate, Sales $290.800M Beat $280.196M Estimate - ANI Pharmaceuticals Raises FY2026 Adj EPS Guidance from $9.19-$9.69 to $9.37-$9.71 vs $9.26 Est; Narrows FY2026 Sales Guidance from $1.080B-$1.140B to $1.085B-$1.125B vs $1.102B Est
ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results 
REPEAT – ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business 
ANI Pharmaceuticals Announces Offer At SEK 11.25 Per Share, About SEK 5.6B ($560M), To Acquire Egetis Therapeutics, Expanding Rare Disease Business 
ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business
Your note
Sign in to keep a note on ANIP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CAREY STEPHEN P. | Chief Financial Officer | Sale | Sep 28, 2026 | 168,993 |
| COOK MEREDITH | General Counsel | Sale | Oct 12, 2026 | 73,424 |
| DAVIS KRISTA | Officer | Sale | Mar 8, 2026 | 51,946 |
| GASSERT CHAD | Officer | Stock Award(Grant) | Feb 25, 2026 | 233,406 |
| GUTWERG ORI | Officer | Sale | Aug 9, 2026 | 75,534 |
| HAUGHEY THOMAS J | Director | Sale | Jun 7, 2026 | 38,878 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 13.02% | 2,958,646 | 210.80M | Jun 29, 2026 |
| Soleus Capital Management, L.P. | 3.82% | 867,760 | 61.83M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.69% | 838,224 | 59.72M | Jun 29, 2026 |
| State Street Corporation | 3.66% | 831,647 | 59.25M | Jun 29, 2026 |
| Dimensional Fund Advisors LP | 3.21% | 728,748 | 51.92M | Sep 29, 2026 |
| Tang Capital Management, LLC | 3.11% | 707,500 | 50.41M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.28% | 1,198,642 | 85.40M | Sep 29, 2026 |
| American Century ETF Trust-Avantis U.S. Small Cap Value ETF | 3.28% | 745,302 | 53.10M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.68% | 609,433 | 43.42M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.33% | 529,877 | 37.75M | Sep 29, 2026 |
| OBERWEIS FUNDS-Oberweis Micro-Cap Fund | 1.13% | 256,300 | 18.26M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.99% | 224,536 | 16.00M | Aug 30, 2026 |